688117.SH
圣诺生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 24.20
−6.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 801.4M | 741.5M | 456.1M | 435.0M | 395.7M |
| Cost of Revenue | 331.1M | 314.0M | 191.7M | 157.6M | 136.6M |
| Gross Profit | 470.3M | 427.5M | 264.4M | 277.4M | 259.1M |
| Operating Expenses | |||||
| R&D Expense | 60.9M | 54.9M | 49.2M | 29.0M | 23.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 76.7M | 81.3M | 61.7M | 53.9M | 45.7M |
| Selling & Marketing Expense | 73.4M | 57.7M | 66.3M | 108.0M | 113.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 237.4M | 217.2M | 191.0M | 199.8M | 185.4M |
| Cost and Expenses | 568.5M | 531.2M | 382.7M | 357.5M | 322.0M |
| Operating Income (EBIT) | 221.3M | 202.0M | 62.1M | 81.1M | 72.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 209.6M | 189.1M | 61.5M | 80.1M | 72.4M |
| Income Tax Expense | 32.4M | 31.2M | 11.7M | 9.8M | 7.9M |
| Bottom Line | |||||
| Net Income | 177.2M | 157.9M | 50.0M | 70.3M | 64.5M |
| Earnings from Cont. Ops | 177.2M | 157.9M | 49.8M | 70.3M | 64.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 177.2M | 157.9M | 50.0M | 70.3M | 64.5M |
| Per Share | |||||
| Basic EPS | CN¥1.13 | CN¥1.00 | CN¥0.32 | CN¥0.63 | CN¥0.58 |
| Diluted EPS | CN¥1.13 | CN¥1.00 | CN¥0.32 | CN¥0.62 | CN¥0.58 |
| Revenue Per Share | CN¥5.07 | CN¥4.70 | CN¥2.92 | CN¥3.90 | CN¥3.56 |
| Shares | |||||
| Basic Shares Outstanding | 158.0M | 157.9M | 156.3M | 111.6M | 111.2M |
| Diluted Shares Outstanding | 158.0M | 157.9M | 156.3M | 111.6M | 111.2M |
| Profitability Metrics | |||||
| EBITDA | — | 260.0M | 97.8M | 110.2M | 97.8M |
| D&A | — | 58.0M | 35.7M | 29.1M | 25.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026